Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065123 | 0.78 | GSK3B (0.47) | GSK3B | |
| SCHEMBL4382493 | 0.77 | CSNK2A2 (0.36) | GSK3BADORA2BCAMKK2OPRK1 | |
| SCHEMBL2064851 | 0.74 | GSK3B (0.48) | GSK3B | |
| SCHEMBL4386511 | 0.73 | ADORA2B (0.32) | GSK3BADORA2BCAMKK2 | |
| SCHEMBL2064447 | 0.69 | GSK3B (0.50) | GSK3B | |
| SCHEMBL1832336 | 0.69 | GSK3B (0.47) | GSK3B | |
| SCHEMBL2064259 | 0.67 | GSK3B (0.43) | GSK3B | |
| SCHEMBL1834667 | 0.65 | GSK3B (0.51) | GSK3B | |
| SCHEMBL3577559 | 0.64 | GSK3B (0.35) | GSK3B | |
| SCHEMBL4380719 | 0.64 | GSK3B (0.44) | GSK3BCAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198287-B2 | Substituted heteroaryl pyridopyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | disclosed |
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-12-10 | — | — | US | disclosed |
| EP-2121635-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | GSK3B, GSK3A, GSKIP | GSK3B 1/4885ADORA2B 1224/4885GABRA1 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.